Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
total number of shares of the Company as of March 31, 2024
total number of shares of the Company as of March 31, 2024
total number of shares of the Company as of March 31, 2024
total number of shares of the Company as of March 31, 2024
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
DBV is sponsoring a non-CME Product Theater titled “Importance of Early Intervention for Peanut Allergy.” Professors Hugh Sampson, M.D.
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with NATIXIS ODDO BHF.
total number of shares of the Company as of November 30, 2023
total number of shares of the Company as of November 30, 2023
Company to host investor conference call and webcast at 5:00pm ET today, Thursday, November 9th, to discuss the results.
total number of shares of the Company as of October 31, 2023
total number of shares of the Company as of October 31, 2023
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.